{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:18:17Z","timestamp":1788135497210,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Gaucher disease type 1 (GD1) is a multisystem lysosomal disorder in which treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) improves key clinical parameters. However, many patients continue to experience persistent symptoms that are not captured by traditional disease markers. This study evaluated the relationship between pain, fatigue, and health-related quality of life (HRQoL) among treated adults with GD1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this cross-sectional study, adults with GD1 receiving ERT or SRT (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200997) completed an online survey including the 36-item Short Form Survey (SF-36), PROMIS\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Fatigue and Pain Interference Short Forms, and the Treatment Satisfaction Questionnaire for Medication\u00a9. Associations between demographic factors, treatment variables, symptoms, and HRQoL were assessed using correlation analyses, t-tests, ANOVA, and multiple regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pain and fatigue were strong, independent predictors of both physical and mental HRQoL, with age additionally predicting physical HRQoL. Significant negative correlations were observed between pain and HRQoL (physical and mental), as well as between fatigue and HRQoL. Participants reported significantly lower HRQoL compared with U.S. population norms across 7 of 8 SF-36 domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Persistent pain and fatigue represent major, under-recognized drivers of impaired quality of life in treated GD1, indicating that current therapies do not fully address the symptomatic burden of disease. These findings support routine integration of validated patient-reported outcome measures into clinical care and highlight the need for adjunctive and mechanism-based approaches to improve patient-centered outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04452-w","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:46:44Z","timestamp":1781610404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["persistent pain and fatigue drive reduced quality of life in treated Gaucher disease type 1: a cross-sectional analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2281-0403","authenticated-orcid":false,"given":"Shauna L.","family":"Mangum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H. A.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Packman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-8232","authenticated-orcid":false,"given":"Beth","family":"Tigges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"4452_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/ijms18020441","volume":"18","author":"J Stirnemann","year":"2017","unstructured":"Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441. https:\/\/doi.org\/10.3390\/ijms18020441.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4452_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ajh.21888","volume":"86","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Cappellini MD, Lukina E, \u00d6zsan H, Pascual SM, Rosenbaum H, et al. A reappraisal of Gaucher disease: diagnosis and disease management algorithms. Am J Hematol. 2010;86(1):110\u20135.","journal-title":"Am J Hematol"},{"issue":"2","key":"4452_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","volume":"22","author":"L Nalysnyk","year":"2017","unstructured":"Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22(2):65\u201373. https:\/\/doi.org\/10.1080\/10245332.2016.1240391.","journal-title":"Hematology"},{"issue":"7","key":"4452_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1310\/hpj5107-553","volume":"51","author":"A Van Rossum","year":"2016","unstructured":"Van Rossum A, Holsopple M. Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options. Hosp Pharm. 2016;51(7):553\u201363. https:\/\/doi.org\/10.1310\/hpj5107-553.","journal-title":"Hosp Pharm"},{"key":"4452_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","volume":"117","author":"M Balwani","year":"2016","unstructured":"Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117:95\u2013103. https:\/\/doi.org\/10.1016\/j.ymgme.2015.09.002.","journal-title":"Mol Genet Metab"},{"key":"4452_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-017-0700-7","volume":"12","author":"G Devigili","year":"2017","unstructured":"Devigili G, De Filippo M, Ciana G, Dardis A, Lettieri C, Rinaldo S, et al. Chronic pain in Gaucher disease: skeletal or neuropathic origin? Orphanet J Rare Dis. 2017;12:148. https:\/\/doi.org\/10.1186\/s13023-017-0700-7.","journal-title":"Orphanet J Rare Dis"},{"key":"4452_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00223-014-9923-y","volume":"95","author":"G Marcucci","year":"2014","unstructured":"Marcucci G, Zimran A, Bembi B, Kanis J, Reginster JY, Rizzoli R, et al. Gaucher disease and bone manifestations. Calcif Tissue Int. 2014;95:477\u201394. https:\/\/doi.org\/10.1007\/s00223-014-9923-y.","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"4452_CR8","doi-asserted-by":"publisher","first-page":"E449","DOI":"10.1002\/ajh.24486","volume":"91","author":"G Drelichman","year":"2016","unstructured":"Drelichman G, Escobar NF, Basack N, et al. Skeletal involvement in Gaucher disease: an observational multicenter study of prognostic factors in Argentine patients. Am J Hematol. 2016;91(10):E449\u201353. https:\/\/doi.org\/10.1002\/ajh.24486.","journal-title":"Am J Hematol"},{"key":"4452_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13023-016-0435-x","volume":"11","author":"ZY Chen","year":"2016","unstructured":"Chen ZY, Pappadopulos E, Wajnrajch M, et al. Rethinking fatigue in Gaucher disease. Orphanet J Rare Dis. 2016;11:53. https:\/\/doi.org\/10.1186\/s13023-016-0435-x.","journal-title":"Orphanet J Rare Dis"},{"key":"4452_CR10","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.25107\/2474-1655.2644","volume":"9","author":"Z Hexner-Erlichman","year":"2024","unstructured":"Hexner-Erlichman Z, Rosenbaum H. Fatigue in Gaucher disease, a key quality-of-life concern: A case series. Ann Clin Case Rep. 2024;9:2644. https:\/\/doi.org\/10.25107\/2474-1655.2644.","journal-title":"Ann Clin Case Rep"},{"issue":"18","key":"4452_CR11","doi-asserted-by":"publisher","first-page":"9912","DOI":"10.3390\/ijms22189912","volume":"22","author":"JC Serfecz","year":"2021","unstructured":"Serfecz JC, Saadin A, Santiago CP, Zhang Y, Bentzen SM, Vogel SN, Feldman RA. C5a activates a pro-inflammatory gene expression profile in human Gaucher iPSC-derived macrophages. Int J Mol Sci. 2021;22(18):9912. https:\/\/doi.org\/10.3390\/ijms22189912.","journal-title":"Int J Mol Sci"},{"key":"4452_CR12","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.2147\/DDDT.S77760","volume":"9","author":"LL Bennett","year":"2015","unstructured":"Bennett LL, Turcotte K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther. 2015;9:4639\u201347. https:\/\/doi.org\/10.2147\/DDDT.S77760.","journal-title":"Drug Des Devel Ther"},{"key":"4452_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000440865","volume":"83","author":"A Dandana","year":"2016","unstructured":"Dandana A, Khelifa SB, Chahed H, Miled A. Gaucher disease: clinical, biological and therapeutic aspects. Pathobiology. 2016;83:13\u201323. https:\/\/doi.org\/10.1159\/000440865.","journal-title":"Pathobiology"},{"issue":"2","key":"4452_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","volume":"13","author":"SE Gary","year":"2018","unstructured":"Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab. 2018;13(2):107\u201318. https:\/\/doi.org\/10.1080\/17446651.2018.1445524.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"4452_CR15","doi-asserted-by":"publisher","first-page":"107667","DOI":"10.1016\/j.ymgme.2023.107667","volume":"140","author":"F Camou","year":"2023","unstructured":"Camou F, Lagadec A, Coutinho A, Berger ML, Cador-Rousseau B, Gaches F, Belmatoug N. Patient-reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: the ELIPRO study. Mol Genet Metab. 2023;140(3):107667. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107667.","journal-title":"Mol Genet Metab"},{"key":"4452_CR16","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/jcm13123588","volume":"13","author":"D Elstein","year":"2024","unstructured":"Elstein D, Belmatoug N, Bembi B, Deegan P, Fernandez-Sasso D, Giraldo P, et al. Twelve years of the Gaucher outcomes survey (GOS): insights, achievements, and lessons learned from a global patient registry. J Clin Med. 2024;13:3588. https:\/\/doi.org\/10.3390\/jcm13123588.","journal-title":"J Clin Med"},{"key":"4452_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","volume":"104","author":"O Goker-Alpan","year":"2011","unstructured":"Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab. 2011;104:438\u201347. https:\/\/doi.org\/10.1016\/j.ymgme.2011.08.004.","journal-title":"Mol Genet Metab"},{"key":"4452_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1023\/A:1008814105603","volume":"7","author":"AM Damiano","year":"1998","unstructured":"Damiano AM, Pastores GM, Ware JE Jr. The health-related quality of life of adults with Gaucher\u2019s disease receiving enzyme replacement therapy. Qual Life Res. 1998;7:373\u201386.","journal-title":"Qual Life Res"},{"key":"4452_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bcmd.2015.09.002","volume":"55","author":"D Elstein","year":"2015","unstructured":"Elstein D, Abrahamov A, Oz A, Arbel N, Baris H, Zimran A. Home therapy infusions with velaglucerase alfa. Blood Cells Mol Dis. 2015;55:415\u20138. https:\/\/doi.org\/10.1016\/j.bcmd.2015.09.002.","journal-title":"Blood Cells Mol Dis"},{"key":"4452_CR20","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D. Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res. 2005;14:453\u201361.","journal-title":"Qual Life Res"},{"key":"4452_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1023\/A:1008878425167","volume":"7","author":"RP Hayes","year":"1998","unstructured":"Hayes RP, Grinzaid KA, Duffey EB, Elsas LJII. The impact of Gaucher disease and its treatment on quality of life. Qual Life Res. 1998;7:521\u201334.","journal-title":"Qual Life Res"},{"key":"4452_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/ajh.25300","volume":"94","author":"E Lukina","year":"2019","unstructured":"Lukina E, Watman N, Dragosky M, Lau H, Arreguin EA, Rosenbaum H, et al. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1. Am J Hematol. 2019;94:29\u201338. https:\/\/doi.org\/10.1002\/ajh.25300.","journal-title":"Am J Hematol"},{"key":"4452_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1023\/A:1008859420641","volume":"8","author":"BJ Masek","year":"1999","unstructured":"Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res. 1999;8:263\u20138.","journal-title":"Qual Life Res"},{"key":"4452_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, et al. Imiglucerase improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet. 2007;71:576\u201388. https:\/\/doi.org\/10.1111\/j.1399-0004.2007.00811.x.","journal-title":"Clin Genet"},{"key":"4452_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/ajmg.a.61533","volume":"182A","author":"AG Alioto","year":"2020","unstructured":"Alioto AG, Gomez R, Moses J, Paternostro J, Packman S, Packman W. Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease type 1. Am J Med Genet A. 2020;182A:1130\u201342. https:\/\/doi.org\/10.1002\/ajmg.a.61533.","journal-title":"Am J Med Genet A"},{"key":"4452_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13023-021-01963-6","volume":"16","author":"X Qi","year":"2021","unstructured":"Qi X, Xu J, Shan L, Li Y, Cui Y, Liu H, Wang K, Gao L, Kang Z, Wu Q. Economic burden and health-related quality of life of ultra-rare Gaucher disease in China. Orphanet J Rare Dis. 2021;16:358. https:\/\/doi.org\/10.1186\/s13023-021-01963-6.","journal-title":"Orphanet J Rare Dis"},{"key":"4452_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","volume":"10","author":"NJ Weinreb","year":"2015","unstructured":"Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, Amato D. Evaluation of disease burden and response to treatment using DS3. Orphanet J Rare Dis. 2015;10:64. https:\/\/doi.org\/10.1186\/s13023-015-0280-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4452_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","volume":"71","author":"A Zimran","year":"1992","unstructured":"Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E. Gaucher disease: clinical features of 53 patients. Med (Baltim). 1992;71(6):337\u201353.","journal-title":"Med (Baltim)"},{"key":"4452_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/8904_2012_136","volume":"7","author":"FL Oliveira","year":"2012","unstructured":"Oliveira FL, Alegra T, Dornelles A, Krug BC, Netto CBO, Sica da Rocha N, Picon PD. Quality of life of Brazilian patients with Gaucher disease and Fabry disease. JIMD Rep. 2012;7:31\u20137. https:\/\/doi.org\/10.1007\/8904_2012_136.","journal-title":"JIMD Rep"},{"issue":"Suppl 5","key":"4452_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations. Semin Hematol. 2004;41(Suppl 5):15\u201322. https:\/\/doi.org\/10.1053\/j.seminhematol.2004.07.010.","journal-title":"Semin Hematol"},{"key":"4452_CR31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C. Long-term clinical outcomes after 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36:543\u201353. https:\/\/doi.org\/10.1007\/s10545-012-9528-4.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 1","key":"4452_CR32","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1182\/blood-2018-99-117289","volume":"132","author":"PK Mistry","year":"2018","unstructured":"Mistry PK, Charrow J, Cox T, Lukina E, Marinakis T, Foster MC, Gaemers SJM, Peterschmitt J. Long-term effects of oral eliglustat on skeletal manifestations. Blood. 2018;132(Suppl 1):2396. https:\/\/doi.org\/10.1182\/blood-2018-99-117289.","journal-title":"Blood"},{"issue":"2","key":"4452_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","volume":"7","author":"HC Andersson","year":"2005","unstructured":"Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakesh-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ. Individualization of long-term enzyme replacement therapy. Genet Med. 2005;7(2):105\u201310. https:\/\/doi.org\/10.1097\/01.GIM.0000153660.88672.3C.","journal-title":"Genet Med"},{"issue":"9","key":"4452_CR34","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ajh.26276","volume":"96","author":"PK Mistry","year":"2021","unstructured":"Mistry PK, Lukina E, Ben Turkia H, et al. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results. Am J Hematol. 2021;96(9):1156\u201365. https:\/\/doi.org\/10.1002\/ajh.26276.","journal-title":"Am J Hematol"},{"key":"4452_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13023-023-02939-4","volume":"18","author":"I Serrano-Gonzalo","year":"2023","unstructured":"Serrano-Gonzalo I, Irun P, Alfonso P, Giraldo P. Real-world effectiveness and safety of eliglustat. Orphanet J Rare Dis. 2023;18:262. https:\/\/doi.org\/10.1186\/s13023-023-02939-4.","journal-title":"Orphanet J Rare Dis"},{"key":"4452_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ajmg.c.30217","volume":"151C","author":"DA Stevenson","year":"2009","unstructured":"Stevenson DA, Carey JC. Health-related quality of life measures in genetic disorders. Am J Med Genet C Semin Med Genet. 2009;151\u00a0C:255\u201360.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"4452_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap). J Biomed Inf. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inf"},{"key":"4452_CR38","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium. J Biomed Inf. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inf"},{"issue":"6","key":"4452_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"3","key":"4452_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","volume":"31","author":"CA McHorney","year":"1993","unstructured":"McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247\u201363.","journal-title":"Med Care"},{"issue":"6846","key":"4452_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","volume":"305","author":"JE Brazier","year":"1992","unstructured":"Brazier JE, Harper R, Jones NM, O\u2019Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160\u20134. https:\/\/doi.org\/10.1136\/bmj.305.6846.160.","journal-title":"BMJ"},{"key":"4452_CR42","volume-title":"SF-36 physical and mental health summary scales: a user\u2019s manual","author":"JE Ware Jr","year":"1994","unstructured":"Ware JE Jr, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user\u2019s manual. Boston: Health Assessment Lab; 1994."},{"key":"4452_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of TSQM. Health Qual Life Outcomes. 2004;2:12. https:\/\/doi.org\/10.1186\/1477-7525-2-12.","journal-title":"Health Qual Life Outcomes"},{"key":"4452_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.pain.2010.04.025","volume":"150","author":"D Amtmann","year":"2010","unstructured":"Amtmann D, Cook KF, Jensen MP, et al. Development of PROMIS fatigue item bank. Pain. 2010;150:173\u201382. https:\/\/doi.org\/10.1016\/j.pain.2010.04.025.","journal-title":"Pain"},{"issue":"2","key":"4452_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3. Behav Res Methods. 2007;39(2):175\u201391. https:\/\/doi.org\/10.3758\/BF03193146.","journal-title":"Behav Res Methods"},{"key":"4452_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N. ICGG Gaucher Registry (NCT00358943) investigators. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132:100\u201311. https:\/\/doi.org\/10.1016\/j.ymgme.2020.12.295.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"4452_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1089\/acm.2009.0442","volume":"16","author":"HT Nguyen","year":"2010","unstructured":"Nguyen HT, Grzywacz JG, Lang W, Walkup M, Arcury TA. Effects of complementary therapy. J Altern Complement Med. 2010;16(7):701\u20136. https:\/\/doi.org\/10.1089\/acm.2009.0442.","journal-title":"J Altern Complement Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04452-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04452-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:04:41Z","timestamp":1788134681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04452-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4452"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04452-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research received IRB approval as an exemption for consent and authorization to participate in a research study from the University of New Mexico Health Science Center, IRB study ID 23\u2013414.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"302"}}